Literature DB >> 11091504

Significant Correlation between the Presence of Type W Collagen in the Duct Wall and the Development of Wide Intraductal Cancerous Extension in Breast Cancer.

.   

Abstract

To identify the characteristics of cases with an wide intraductal cancerous extension (WICE), we examined the relationship between WICE and type IV collagen distribution, and the relationship between WICE and the content of the proliferation-associated proteins in human breast cancer. The immunohistochemical distribution of type IV collagen and proliferating cell nuclear antigen (PCNA) were investigated in formalin-fixed tissue sections from 21 breast cancer cases. We demonstrated a significant correlation (p=0.014) between the presence of WICE and immunostaining of type IV collagen in the cancerous ducts (ducts occupied by cancer cells) in the central invasive area of breast cancer. However, no correlation was found between the presence of WICE and the PCNA index (percentage of positive cells per 1000 tumor cells). These findings suggest that the lack of the process of the loss of type IV collagen in the duct wall is more important than the nature of the tumor cells in the development of WICE.

Entities:  

Year:  1994        PMID: 11091504     DOI: 10.1007/BF02967372

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  14 in total

1.  Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression.

Authors:  A D'Errico; S Garbisa; L A Liotta; V Castronovo; W G Stetler-Stevenson; W F Grigioni
Journal:  Mod Pathol       Date:  1991-03       Impact factor: 7.842

2.  Involvement of nipple and areola in early breast cancer.

Authors:  T Morimoto; K Komaki; K Inui; A Umemoto; H Yamamoto; K Harada; K Inoue
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

3.  Loss of basement membrane components by invasive tumors but not by their benign counterparts.

Authors:  S H Barsky; G P Siegal; F Jannotta; L A Liotta
Journal:  Lab Invest       Date:  1983-08       Impact factor: 5.662

4.  Prognostic significance of type IV collagen and laminin immunoreactivity in urothelial carcinomas of the bladder.

Authors:  R F Schapers; R P Pauwels; M G Havenith; A W Smeets; P A van den Brandt; F T Bosman
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

5.  Correlation between laminin and type IV collagen distribution in breast carcinomas, and estrogen receptors expression, lymph node and vascular involvement.

Authors:  C Charpin; L Andrac; M C Habib; H Vacheret; M N Lavaut; L Xerri; D Figarella-Branger; P Casanova; M Toga
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

6.  Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma.

Authors:  A T Levy; V Cioce; M E Sobel; S Garbisa; W F Grigioni; L A Liotta; W G Stetler-Stevenson
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

7.  Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.

Authors:  R Bravo; R Frank; P A Blundell; H Macdonald-Bravo
Journal:  Nature       Date:  1987 Apr 2-8       Impact factor: 49.962

8.  The value of immunohistochemistry for collagen IV expression in colorectal carcinomas.

Authors:  G J Offerhaus; F M Giardiello; J A Bruijn; T Stijnen; E N Molyvas; G J Fleuren
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

9.  Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.

Authors:  P A Hall; D A Levison; A L Woods; C C Yu; D B Kellock; J A Watkins; D M Barnes; C E Gillett; R Camplejohn; R Dover
Journal:  J Pathol       Date:  1990-12       Impact factor: 7.996

10.  Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy.

Authors:  S J Schnitt; J L Connolly; J R Harris; S Hellman; R B Cohen
Journal:  Cancer       Date:  1984-03-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.